JV moves Immucor closer to direct presence in Japan:
This article was originally published in Clinica
Executive Summary
Immucor is to take a majority interest in a new joint venture with the Japanese distributor of its blood transfusion diagnostics, Kainos Laboratories. It will pay $3.7m for a 51% initial stake in the venture, which will assume responsibility for Immucor's distribution in Japan. Eventually, the Norcross, Georgia-based company expects to buy the business outright and assume direct distribution of its products in Japan, the third-largest transfusion diagnostics market after the US and Europe.
You may also be interested in...
Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
World-First Nod For Yuhan's Lung Cancer Drug, In Korea
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes Gains US FDA Clearance For Velys Robot For Total Knee Surgery
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: